Tu1503 – Usage of Ppi Reduces the Svr Rate for Hiv-Hcv Coinfected Patients Using Ledipasvir/Sofosbuvir: A Real-World Study from Multicenter Va Cohort

MLA

Mohamed G. Hashem, et al. “Tu1503 – Usage of Ppi Reduces the Svr Rate for Hiv-Hcv Coinfected Patients Using Ledipasvir/Sofosbuvir: A Real-World Study from Multicenter Va Cohort.” Gastroenterology, vol. 156, May 2019, p. S-1345. EBSCOhost, https://doi.org/10.1016/s0016-5085(19)40383-1.

APA

Mohamed G. Hashem, Lawrence P. Park, Susanna Naggie, Austin Chan, Tzu-Hao Lee, Mary L. Townsend, Steve S. Choi, William E. Bryan, Cynthia A. Moylan, & Rachel B. Britt. (2019). Tu1503 – Usage of Ppi Reduces the Svr Rate for Hiv-Hcv Coinfected Patients Using Ledipasvir/Sofosbuvir: A Real-World Study from Multicenter Va Cohort. Gastroenterology, 156, S-1345. https://doi.org/10.1016/s0016-5085(19)40383-1

Chicago

Mohamed G. Hashem, Lawrence P. Park, Susanna Naggie, Austin Chan, Tzu-Hao Lee, Mary L. Townsend, Steve S. Choi, William E. Bryan, Cynthia A. Moylan, and Rachel B. Britt. 2019. “Tu1503 – Usage of Ppi Reduces the Svr Rate for Hiv-Hcv Coinfected Patients Using Ledipasvir/Sofosbuvir: A Real-World Study from Multicenter Va Cohort.” Gastroenterology 156 (May): S-1345. doi:10.1016/s0016-5085(19)40383-1.